Richard S. Finn, MD - Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook - a podcast by PVI, PeerView Institute for Medical Education

Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.

Further episodes of PeerView Immunology

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education